| 2016-10-18 07:18:08|
PFE 07:18 10/18 10/18/16
Pfizer risk/reward favorable at current levels, says UBS
UBS analyst Marc Goodman likes the current risk/reward for Pfizer shares. He believes the shares will move higher as top-line growth improves, its pipeline appreciation gets better, and management continues to be aggressive with M&A. Goodman reiterated his Buy rating and $38 price target on Pfizer shares.